share_log

EyePoint Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

EyePoint Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

EyePoint Pharmaceuticals | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/09 04:13

Moomoo AI 已提取核心訊息

EyePoint Pharmaceuticals reported Q2 2024 total revenues of $9.5 million, a 4% increase year-over-year, driven by $7.8 million in license and collaboration revenue. Product sales declined to $1.1 million from $5.3 million last year following the Alimera YUTIQ licensing agreement. Net loss widened to $30.8 million from $22.9 million in Q2 2023.Research and development expenses increased 90% to $29.8 million, reflecting a $5 million milestone payment for Phase 2 trial completion and increased clinical development activities for DURAVYU. The company maintained a strong balance sheet with $280.2 million in cash and investments as of June 30, 2024, expected to fund operations through Phase 3 wet AMD topline data in 2026.The company received an FDA Warning Letter in July 2024 regarding YUTIQ manufacturing at its Watertown facility, requiring implementation of additional control procedures. Management believes YUTIQ supply should not be materially interrupted and other products in development, including DURAVYU, are not impacted. The company completed enrollment in the Phase 2 VERONA trial for diabetic macular edema and aligned with FDA on Phase 3 trials for wet AMD.
EyePoint Pharmaceuticals reported Q2 2024 total revenues of $9.5 million, a 4% increase year-over-year, driven by $7.8 million in license and collaboration revenue. Product sales declined to $1.1 million from $5.3 million last year following the Alimera YUTIQ licensing agreement. Net loss widened to $30.8 million from $22.9 million in Q2 2023.Research and development expenses increased 90% to $29.8 million, reflecting a $5 million milestone payment for Phase 2 trial completion and increased clinical development activities for DURAVYU. The company maintained a strong balance sheet with $280.2 million in cash and investments as of June 30, 2024, expected to fund operations through Phase 3 wet AMD topline data in 2026.The company received an FDA Warning Letter in July 2024 regarding YUTIQ manufacturing at its Watertown facility, requiring implementation of additional control procedures. Management believes YUTIQ supply should not be materially interrupted and other products in development, including DURAVYU, are not impacted. The company completed enrollment in the Phase 2 VERONA trial for diabetic macular edema and aligned with FDA on Phase 3 trials for wet AMD.
EyePoint Pharmaceuticals報告2024年第二季度總營業收入爲950萬美元，同比增加4%，主要受到780萬美元的許可和合作收入推動。產品銷售從去年的530萬美元下降至110萬美元，原因是Alimera YUTIQ許可協議的影響。淨虧損從2023年第二季度的2290萬美元擴大至3080萬美元。研發費用增加90%至2980萬美元，這反映了爲第二階段試驗完成支付的500萬美元里程碑款，以及DURAVYU的臨牀開發活動增加。截至2024年6月30日，公司保持強勁的資產負債表，現金和投資總額爲28020萬美元，預計將爲2026年溼性AMD頂線數據的第三階段運營提供資金。該公司於202...展開全部
EyePoint Pharmaceuticals報告2024年第二季度總營業收入爲950萬美元，同比增加4%，主要受到780萬美元的許可和合作收入推動。產品銷售從去年的530萬美元下降至110萬美元，原因是Alimera YUTIQ許可協議的影響。淨虧損從2023年第二季度的2290萬美元擴大至3080萬美元。研發費用增加90%至2980萬美元，這反映了爲第二階段試驗完成支付的500萬美元里程碑款，以及DURAVYU的臨牀開發活動增加。截至2024年6月30日，公司保持強勁的資產負債表，現金和投資總額爲28020萬美元，預計將爲2026年溼性AMD頂線數據的第三階段運營提供資金。該公司於2024年7月收到了FDA關於其Watertown設施YUTIQ製造的警告信，要求實施額外的控制程序。管理層相信YUTIQ的供應不會受到實質性干擾，其他在開發中的產品，包括DURAVYU，也不受影響。該公司完成了糖尿病性黃斑水腫的第二階段VERONA試驗的入組，並與FDA就溼性AMD的第三階段試驗達成一致。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。